Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma
- Conditions
- severe asthmasteroid-dependent asthma10006436
- Registration Number
- NL-OMON30375
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
- 18-65 years
- pulmonologist's diagnosis of severe asthma
- daily or alternate day oral corticosteroid therapy for at least 1 month before entering into the study
- maintenance high dose inhaled corticosteroids (at least 1600 mcg/day beclomethasone equivalent) and long- and short acting bronchodilators for more than one year
Exclusion Criteria
- The patient is not able to perform adequate measurements of FENO at home
- The patient has no mobile phone or internet access
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Cumulative dose of oral corticosteroids, symptoms (ACQ), quality of life<br /><br>(AQLQ), patient's health state (VAS). </p><br>
- Secondary Outcome Measures
Name Time Method <p>EQ-5D, SF-12, lung function, exacerbations, emergency visits, hospitalisations,<br /><br>steroid side effects </p><br>